1. Phylogeny  
CDC7 is an evolutionarily conserved serine/threonine protein kinase that plays a central role in initiating DNA replication. Orthologs of CDC7 have been identified in a broad range of eukaryotic organisms, including unicellular yeasts such as Saccharomyces cerevisiae and Schizosaccharomyces pombe as well as higher eukaryotes like mammals, where the human protein shares significant sequence and functional homology with its yeast counterparts (kim2004geneticdissectionof pages 1-2, montagnoli2002drf1anovel pages 1-2, malumbres2011physiologicalrelevanceof pages 8-10). In phylogenetic classifications, CDC7 is placed within a group of cell cycle regulatory kinases that are part of the core machinery ensuring accurate genome duplication. The presence of regulatory subunits such as Dbf4 (also referred to as ASK or Drf1 in certain species) that are required for CDC7 activation further supports its preserved function across species, indicating that the CDC7–Dbf4 (also known as DDK) complex emerged early in eukaryotic evolution and has been stringently conserved in the Last Eukaryotic Common Ancestor and its descendants (kim2004geneticdissectionof pages 1-2, montagnoli2002drf1anovel pages 1-2).

2. Reaction Catalyzed  
CDC7 catalyzes the phosphorylation of serine/threonine residues on protein substrates by transferring a phosphate group from ATP to the hydroxyl group of the substrate. The chemical reaction can be formally written as: ATP + [protein]-(L-serine or L-threonine) → ADP + [protein]-(L-serine/threonine)-phosphate + H⁺, with the phosphorylation reaction being central to the regulation of DNA replication initiation (masai2009drugdesignwith pages 1-2, labib2010howdocdc7 pages 12-13).

3. Cofactor Requirements  
The catalytic activity of CDC7, typical of serine/threonine kinases, depends on the presence of divalent metal ions as cofactors. In particular, Mg²⁺ is required to coordinate the transfer of the phosphate group from ATP, thereby stabilizing the transition state during catalysis (masai2009drugdesignwith pages 1-2, labib2010howdocdc7 pages 12-13).

4. Substrate Specificity  
CDC7 displays a high substrate specificity for proteins that are critical to the initiation of DNA replication. It phosphorylates key components of the minichromosome maintenance (MCM) helicase complex—including MCM2, MCM4, and MCM6—which is necessary for the activation of replication origins and subsequent DNA synthesis (davey2011asynthetichuman pages 8-9, masai2009drugdesignwith pages 3-5). In addition, CDC7 phosphorylates the replication checkpoint mediator Claspin, particularly within its Chk1-binding domain, which is essential for the efficient activation of the replication stress checkpoint (yang2019cdc7activatesreplication pages 10-11). The phosphorylation consensus appears to favor serine or threonine residues positioned within sequences that facilitate substrate recognition by the kinase, often in proximity to acidic residues (masai2009drugdesignwith pages 3-5, yang2019cdc7activatesreplication pages 10-11).

5. Structure  
CDC7 is organized around a central catalytic kinase domain that adopts the typical bilobal structure found among serine/threonine kinases. This domain is composed of an N-terminal lobe, which contains the ATP-binding pocket, and a larger C-terminal lobe that houses the activation loop, the catalytic loop, and structural motifs such as the DFG motif critical for binding the required Mg²⁺–ATP complex (masai2009drugdesignwith pages 8-9). Structural studies, including crystallographic analyses and cryo-electron microscopy of the CDC7–Dbf4 complex, have revealed that binding to its regulatory subunit induces conformational changes that optimize the orientation of the catalytic residues and enhance ATP affinity (montagnoli2002drf1anovel pages 10-11, cheng2022structuralinsightinto pages 11-12). Moreover, the interaction with Dbf4 not only stimulates the kinase activity by aligning the catalytic elements, but also facilitates substrate recognition through additional docking interfaces that may be present outside the conserved kinase core. Although detailed three-dimensional structures from high-resolution experimental methods are available for the complex, the core CDC7 catalytic unit remains highly conserved in its overall fold and key regulatory features, including a C-helix that participates in hydrophobic spine formation and an activation loop whose phosphorylation status may contribute to its regulation (masai2009drugdesignwith pages 8-9, montagnoli2002drf1anovel pages 10-11).

6. Regulation  
The enzymatic activity of CDC7 is tightly regulated by multiple mechanisms that ensure coordinated initiation of DNA replication. Primarily, CDC7 requires binding to its regulatory subunit Dbf4 (and in some cases Drf1), which is essential for its activation, as Dbf4 induces conformational changes that facilitate ATP binding and substrate recognition (davey2011asynthetichuman pages 9-9, montagnoli2002drf1anovel pages 10-11). The abundance of Dbf4 is itself cell cycle regulated, with peak levels during S phase followed by degradation through the action of the anaphase-promoting complex (APC), thereby temporally limiting CDC7 activity (malumbres2011physiologicalrelevanceof pages 28-29, masai2009drugdesignwith pages 2-3). Additionally, CDC7 undergoes post-translational modifications such as phosphorylation, which further modulate its activity and interactions with substrates like MCM proteins and Claspin (yang2019cdc7activatesreplication pages 10-11, masai2009drugdesignwith pages 3-5). Regulatory cross-talk with other kinases, including those involved in checkpoint responses (for example, CK1γ1 acting alongside CDC7 to phosphorylate Claspin), underscores a complex network whereby CDC7-driven phosphorylation is integrated with replication stress responses (yang2019cdc7activatesreplication pages 16-17, rainey2013cdc7dependentandindependent pages 8-9).

7. Function  
CDC7 performs a critical role in controlling the initiation of DNA replication, a process fundamental to cell cycle progression. By phosphorylating components of the minichromosome maintenance (MCM) helicase complex, CDC7 converts dormant pre-replicative complexes into active replication forks, thereby ensuring the proper firing of replication origins during the G₁/S phase transition (davey2011asynthetichuman pages 1-1, kim2004geneticdissectionof pages 1-2, malumbres2011physiologicalrelevanceof pages 28-29). In addition to its canonical role in replication initiation, CDC7 also contributes to replication checkpoint activation through the phosphorylation of Claspin’s Chk1-binding domain, which is necessary for timely checkpoint signaling in response to replication stress (yang2019cdc7activatesreplication pages 10-11, rainey2013cdc7dependentandindependent pages 3-4). The activity of CDC7 thus ensures not only the onset of DNA synthesis but also the maintenance of genome stability by coupling replication initiation with the activation of checkpoint pathways that delay cell cycle progression under conditions of DNA damage or replication stress (kim2004geneticdissectionof pages 1-2, malumbres2011physiologicalrelevanceof pages 8-10). Loss or inhibition of CDC7 activity has been demonstrated to result in S-phase arrest, replication fork stalling, and eventual cell death in various experimental models, underscoring its indispensability for cellular proliferation (davey2011asynthetichuman pages 1-1, labib2010howdocdc7 pages 12-13).

8. Other Comments  
Several small-molecule inhibitors targeting CDC7 have been developed, with compounds such as PHA-767491 and XL413 representing key experimental tools in the study of CDC7 function and as potential therapeutic agents in oncology (masai2009drugdesignwith pages 9-10, sasi2014thepotentcdc7dbf4 pages 12-13). These inhibitors act in an ATP-competitive manner by binding to the highly conserved catalytic pocket of CDC7 and disrupting its ability to phosphorylate key replication substrates. In addition, recent reports have explored purine-based derivatives that exhibit selective inhibition of CDC7 activity, with computational docking studies providing insights into structure–activity relationships that may inform the design of next-generation inhibitors (rojasprats2021targetingnuclearprotein pages 14-16, rojasprats2024druggablecavitiesand pages 8-10). Overexpression or aberrant regulation of CDC7 has been associated with replication stress and genomic instability in cancer cells, rendering it an attractive target for anticancer therapies. Furthermore, the emerging role of CDC7 in phosphorylating non-replication substrates, such as the neurodegeneration-associated protein TDP-43, has broadened the therapeutic scope of CDC7 inhibition to include potential applications in neurodegenerative disorders (rojasprats2021targetingnuclearprotein pages 14-16). Genetic studies in model organisms have also demonstrated that defective CDC7 function leads to embryonic lethality and severe cell cycle defects, reflecting its essential role in development and cellular homeostasis (kim2004geneticdissectionof pages 1-2, malumbres2011physiologicalrelevanceof pages 8-10).

9. References  
1. Davey, M. J., Andrighetti, H. J., Ma, X., & Brandl, C. J. (2011). A synthetic human kinase can control cell cycle progression in budding yeast. G3 Genes|Genomes|Genetics, 1:317–325. (davey2011asynthetichuman pages 1-1, davey2011asynthetichuman pages 8-9, davey2011asynthetichuman pages 9-9)  
2. Kim, J. M., & Masai, H. (2004). Genetic dissection of mammalian cdc7 kinase: cell cycle and developmental roles. Cell Cycle, 3:298–302. (kim2004geneticdissectionof pages 1-2, kim2004geneticdissectionof pages 4-5)  
3. Labib, K. (2010). How do cdc7 and cyclin-dependent kinases trigger the initiation of chromosome replication in eukaryotic cells? Genes & Development, 24:1208–1219. (labib2010howdocdc7 pages 12-13)  
4. Malumbres, M. (2011). Physiological relevance of cell cycle kinases. Physiological Reviews, 91:973–1007. (malumbres2011physiologicalrelevanceof pages 28-29)  
5. Masai, H., & Sawa, H. (2009). Drug design with cdc7 kinase: a potential novel cancer therapy target. Drug Design, Development and Therapy, 2:255–264. (masai2009drugdesignwith pages 1-2, masai2009drugdesignwith pages 2-3, masai2009drugdesignwith pages 3-5, masai2009drugdesignwith pages 6-8, masai2009drugdesignwith pages 8-9, masai2009drugdesignwith pages 9-10)  
6. Rainey, M., Harhen, B., Wang, G.-N., Murphy, P., & Santocanale, C. (2013). Cdc7-dependent and -independent phosphorylation of claspin in the induction of the dna replication checkpoint. Cell Cycle, 12:1560–1568. (rainey2013cdc7dependentandindependent pages 8-9, rainey2013cdc7dependentandindependent pages 3-4, rainey2013cdc7dependentandindependent pages 4-6)  
7. Rojas-Prats, E., Martinez-Gonzalez, L., Gonzalo-Consuegra, C., Liachko, N. F., Perez, C., Ramírez, D., Kraemer, B. C., Martin-Requero, Á., Perez, D. I., Gil, C., de Lago, E., & Martinez, A. (2021). Targeting nuclear protein tdp-43 by cell division cycle kinase 7 inhibitors: a new therapeutic approach for amyotrophic lateral sclerosis. European Journal of Medicinal Chemistry, 210:112968. (rojasprats2021targetingnuclearprotein pages 14-16, rojasprats2021targetingnuclearprotein pages 51-55, rojasprats2021targetingnuclearprotein pages 59-62)  
8. Rojas-Prats, E., Martínez-González, L., Gil, C., Ramírez, D., & Martínez, A. (2024). Druggable cavities and allosteric modulators of the cell division cycle 7 (cdc7) kinase. Journal of Enzyme Inhibition and Medicinal Chemistry. (rojasprats2024druggablecavitiesand pages 1-2, rojasprats2024druggablecavitiesand pages 10-11, rojasprats2024druggablecavitiesand pages 8-10)  
9. Sasi, N., Tiwari, K., Soon, F.-F., Bonte, D., Wang, T., Melcher, K., Xu, H., & Weinreich, M. (2014). The potent cdc7-dbf4 (ddk) kinase inhibitor xl413 has limited activity in many cancer cell lines and discovery of potential new ddk inhibitor scaffolds. PLoS ONE, Nov 2014. (sasi2014thepotentcdc7dbf4 pages 12-12, sasi2014thepotentcdc7dbf4 pages 12-13, sasi2014thepotentcdc7dbf4 pages 13-13)  
10. Yang, C.-C., Kato, H., Shindo, M., & Masai, H. (2019). Cdc7 activates replication checkpoint by phosphorylating the chk1-binding domain of claspin in human cells. eLife, Dec 2019. (yang2019cdc7activatesreplication pages 10-11, yang2019cdc7activatesreplication pages 16-17, yang2019cdc7activatesreplication pages 13-14, yang2019cdc7activatesreplication pages 2-3, yang2019cdc7activatesreplication pages 1-2, yang2019cdc7activatesreplication pages 22-23)  
11. Cheng, J., Li, N., Huo, Y., Dang, S., Tye, B., Gao, N., & Zhai, Y. (2022). Structural insight into the mcm double hexamer activation by dbf4-cdc7 kinase. Nature Communications, Mar 2022. (cheng2022structuralinsightinto pages 11-12)  
12. Montagnoli, A., Bosotti, R., Villa, F., Rialland, M., Brotherton, D., Mercurio, C., Berthelsen, J., & Santocanale, C. (2002). Drf1, a novel regulatory subunit for human cdc7 kinase. The EMBO Journal, 21:3171–3181. (montagnoli2002drf1anovel pages 1-2, montagnoli2002drf1anovel pages 10-11)  
13. Nakamura, T., Nakamura-Kubo, M., Nakamura, T., & Shimoda, C. (2002). Novel fission yeast cdc7-dbf4-like kinase complex required for the initiation and progression of meiotic second division. Molecular and Cellular Biology, 22:309–320. (nakamura2002novelfissionyeast pages 11-12)  
14. Mishra, P. K., Wood, H., Stanton, J., Au, W.-C., Eisenstatt, J. R., Boeckmann, L., Sclafani, R. A., Weinreich, M., Bloom, K. S., Thorpe, P. H., & Basrai, M. A. (2021). Cdc7-mediated phosphorylation of cse4 regulates high-fidelity chromosome segregation in budding yeast. Molecular Biology of the Cell, Nov 2021. (mishra2021cdc7mediatedphosphorylationof pages 1-2)  
15. Rainey, M. D., Quinlan, A., Cazzaniga, C., Mijic, S., Martella, O., Krietsch, J., Göder, A., Lopes, M., & Santocanale, C. (2020). Cdc7 kinase promotes mre11 fork processing, modulating fork speed and chromosomal breakage. EMBO Reports, Jun 2020. (rainey2020cdc7kinasepromotes pages 8-11)  
16. Yamada, M., Masai, H., & Bartek, J. (2014). Regulation and roles of cdc7 kinase under replication stress. Cell Cycle, 13:1859–1866, May 2014. (yamada2014regulationandroles pages 1-2)

References

1. (davey2011asynthetichuman pages 1-1): Megan J Davey, Heather J Andrighetti, Xiaoli Ma, and Christopher J Brandl. A synthetic human kinase can control cell cycle progression in budding yeast. G3 Genes|Genomes|Genetics, 1:317-325, Sep 2011. URL: https://doi.org/10.1534/g3.111.000430, doi:10.1534/g3.111.000430. This article has 13 citations.

2. (davey2011asynthetichuman pages 8-9): Megan J Davey, Heather J Andrighetti, Xiaoli Ma, and Christopher J Brandl. A synthetic human kinase can control cell cycle progression in budding yeast. G3 Genes|Genomes|Genetics, 1:317-325, Sep 2011. URL: https://doi.org/10.1534/g3.111.000430, doi:10.1534/g3.111.000430. This article has 13 citations.

3. (davey2011asynthetichuman pages 9-9): Megan J Davey, Heather J Andrighetti, Xiaoli Ma, and Christopher J Brandl. A synthetic human kinase can control cell cycle progression in budding yeast. G3 Genes|Genomes|Genetics, 1:317-325, Sep 2011. URL: https://doi.org/10.1534/g3.111.000430, doi:10.1534/g3.111.000430. This article has 13 citations.

4. (kim2004geneticdissectionof pages 1-2): Jung Min Kim and Hisao Masai. Genetic dissection of mammalian cdc7 kinase: cell cycle and developmental roles. Cell Cycle, 3:298-302, Mar 2004. URL: https://doi.org/10.4161/cc.3.3.730, doi:10.4161/cc.3.3.730. This article has 20 citations and is from a peer-reviewed journal.

5. (kim2004geneticdissectionof pages 4-5): Jung Min Kim and Hisao Masai. Genetic dissection of mammalian cdc7 kinase: cell cycle and developmental roles. Cell Cycle, 3:298-302, Mar 2004. URL: https://doi.org/10.4161/cc.3.3.730, doi:10.4161/cc.3.3.730. This article has 20 citations and is from a peer-reviewed journal.

6. (labib2010howdocdc7 pages 12-13): Karim Labib. How do cdc7 and cyclin-dependent kinases trigger the initiation of chromosome replication in eukaryotic cells? Genes &amp; Development, 24:1208-1219, Jun 2010. URL: https://doi.org/10.1101/gad.1933010, doi:10.1101/gad.1933010. This article has 425 citations.

7. (malumbres2011physiologicalrelevanceof pages 28-29): Marcos Malumbres. Physiological relevance of cell cycle kinases. Physiological Reviews, 91:973-1007, Jul 2011. URL: https://doi.org/10.1152/physrev.00025.2010, doi:10.1152/physrev.00025.2010. This article has 300 citations and is from a highest quality peer-reviewed journal.

8. (masai2009drugdesignwith pages 1-2): H Masai M Sawa. Drug design with cdc7 kinase: a potential novel cancer therapy target. Drug design, development and therapy, 2:255-264, Nov 2009. URL: https://doi.org/10.2147/dddt.s4303, doi:10.2147/dddt.s4303. This article has 53 citations.

9. (masai2009drugdesignwith pages 2-3): H Masai M Sawa. Drug design with cdc7 kinase: a potential novel cancer therapy target. Drug design, development and therapy, 2:255-264, Nov 2009. URL: https://doi.org/10.2147/dddt.s4303, doi:10.2147/dddt.s4303. This article has 53 citations.

10. (masai2009drugdesignwith pages 3-5): H Masai M Sawa. Drug design with cdc7 kinase: a potential novel cancer therapy target. Drug design, development and therapy, 2:255-264, Nov 2009. URL: https://doi.org/10.2147/dddt.s4303, doi:10.2147/dddt.s4303. This article has 53 citations.

11. (masai2009drugdesignwith pages 6-8): H Masai M Sawa. Drug design with cdc7 kinase: a potential novel cancer therapy target. Drug design, development and therapy, 2:255-264, Nov 2009. URL: https://doi.org/10.2147/dddt.s4303, doi:10.2147/dddt.s4303. This article has 53 citations.

12. (masai2009drugdesignwith pages 8-9): H Masai M Sawa. Drug design with cdc7 kinase: a potential novel cancer therapy target. Drug design, development and therapy, 2:255-264, Nov 2009. URL: https://doi.org/10.2147/dddt.s4303, doi:10.2147/dddt.s4303. This article has 53 citations.

13. (masai2009drugdesignwith pages 9-10): H Masai M Sawa. Drug design with cdc7 kinase: a potential novel cancer therapy target. Drug design, development and therapy, 2:255-264, Nov 2009. URL: https://doi.org/10.2147/dddt.s4303, doi:10.2147/dddt.s4303. This article has 53 citations.

14. (rainey2013cdc7dependentandindependent pages 8-9): Michael Rainey, Brendan Harhen, Guan-Nan Wang, Paul Murphy, and Corrado Santocanale. Cdc7-dependent and -independent phosphorylation of claspin in the induction of the dna replication checkpoint. Cell Cycle, 12:1560-1568, May 2013. URL: https://doi.org/10.4161/cc.24675, doi:10.4161/cc.24675. This article has 46 citations and is from a peer-reviewed journal.

15. (rojasprats2021targetingnuclearprotein pages 14-16): Elisa Rojas-Prats, Loreto Martinez-Gonzalez, Claudia Gonzalo-Consuegra, Nicole F. Liachko, Concepción Perez, David Ramírez, Brian C. Kraemer, Ángeles Martin-Requero, Daniel I. Perez, Carmen Gil, Eva de Lago, and Ana Martinez. Targeting nuclear protein tdp-43 by cell division cycle kinase 7 inhibitors: a new therapeutic approach for amyotrophic lateral sclerosis. European Journal of Medicinal Chemistry, 210:112968, Jan 2021. URL: https://doi.org/10.1016/j.ejmech.2020.112968, doi:10.1016/j.ejmech.2020.112968. This article has 50 citations and is from a domain leading peer-reviewed journal.

16. (rojasprats2021targetingnuclearprotein pages 51-55): Elisa Rojas-Prats, Loreto Martinez-Gonzalez, Claudia Gonzalo-Consuegra, Nicole F. Liachko, Concepción Perez, David Ramírez, Brian C. Kraemer, Ángeles Martin-Requero, Daniel I. Perez, Carmen Gil, Eva de Lago, and Ana Martinez. Targeting nuclear protein tdp-43 by cell division cycle kinase 7 inhibitors: a new therapeutic approach for amyotrophic lateral sclerosis. European Journal of Medicinal Chemistry, 210:112968, Jan 2021. URL: https://doi.org/10.1016/j.ejmech.2020.112968, doi:10.1016/j.ejmech.2020.112968. This article has 50 citations and is from a domain leading peer-reviewed journal.

17. (rojasprats2021targetingnuclearprotein pages 59-62): Elisa Rojas-Prats, Loreto Martinez-Gonzalez, Claudia Gonzalo-Consuegra, Nicole F. Liachko, Concepción Perez, David Ramírez, Brian C. Kraemer, Ángeles Martin-Requero, Daniel I. Perez, Carmen Gil, Eva de Lago, and Ana Martinez. Targeting nuclear protein tdp-43 by cell division cycle kinase 7 inhibitors: a new therapeutic approach for amyotrophic lateral sclerosis. European Journal of Medicinal Chemistry, 210:112968, Jan 2021. URL: https://doi.org/10.1016/j.ejmech.2020.112968, doi:10.1016/j.ejmech.2020.112968. This article has 50 citations and is from a domain leading peer-reviewed journal.

18. (rojasprats2024druggablecavitiesand pages 1-2): Elisa Rojas-Prats, Loreto Martínez-González, Carmen Gil, David Ramírez, and Ana Martínez. Druggable cavities and allosteric modulators of the cell division cycle 7 (cdc7) kinase. Journal of Enzyme Inhibition and Medicinal Chemistry, Jan 2024. URL: https://doi.org/10.1080/14756366.2024.2301767, doi:10.1080/14756366.2024.2301767. This article has 1 citations and is from a peer-reviewed journal.

19. (rojasprats2024druggablecavitiesand pages 10-11): Elisa Rojas-Prats, Loreto Martínez-González, Carmen Gil, David Ramírez, and Ana Martínez. Druggable cavities and allosteric modulators of the cell division cycle 7 (cdc7) kinase. Journal of Enzyme Inhibition and Medicinal Chemistry, Jan 2024. URL: https://doi.org/10.1080/14756366.2024.2301767, doi:10.1080/14756366.2024.2301767. This article has 1 citations and is from a peer-reviewed journal.

20. (rojasprats2024druggablecavitiesand pages 8-10): Elisa Rojas-Prats, Loreto Martínez-González, Carmen Gil, David Ramírez, and Ana Martínez. Druggable cavities and allosteric modulators of the cell division cycle 7 (cdc7) kinase. Journal of Enzyme Inhibition and Medicinal Chemistry, Jan 2024. URL: https://doi.org/10.1080/14756366.2024.2301767, doi:10.1080/14756366.2024.2301767. This article has 1 citations and is from a peer-reviewed journal.

21. (sasi2014thepotentcdc7dbf4 pages 12-12): N. Sasi, Kanchan Tiwari, F.-F. Soon, D. Bonte, Tong Wang, K. Melcher, H. Xu, and M. Weinreich. The potent cdc7-dbf4 (ddk) kinase inhibitor xl413 has limited activity in many cancer cell lines and discovery of potential new ddk inhibitor scaffolds. PLoS ONE, Nov 2014. URL: https://doi.org/10.1371/journal.pone.0113300, doi:10.1371/journal.pone.0113300. This article has 43 citations and is from a peer-reviewed journal.

22. (sasi2014thepotentcdc7dbf4 pages 12-13): N. Sasi, Kanchan Tiwari, F.-F. Soon, D. Bonte, Tong Wang, K. Melcher, H. Xu, and M. Weinreich. The potent cdc7-dbf4 (ddk) kinase inhibitor xl413 has limited activity in many cancer cell lines and discovery of potential new ddk inhibitor scaffolds. PLoS ONE, Nov 2014. URL: https://doi.org/10.1371/journal.pone.0113300, doi:10.1371/journal.pone.0113300. This article has 43 citations and is from a peer-reviewed journal.

23. (yang2019cdc7activatesreplication pages 10-11): Chi-Chun Yang, Hiroyuki Kato, Mayumi Shindo, and Hisao Masai. Cdc7 activates replication checkpoint by phosphorylating the chk1-binding domain of claspin in human cells. eLife, Dec 2019. URL: https://doi.org/10.7554/elife.50796, doi:10.7554/elife.50796. This article has 43 citations and is from a domain leading peer-reviewed journal.

24. (yang2019cdc7activatesreplication pages 16-17): Chi-Chun Yang, Hiroyuki Kato, Mayumi Shindo, and Hisao Masai. Cdc7 activates replication checkpoint by phosphorylating the chk1-binding domain of claspin in human cells. eLife, Dec 2019. URL: https://doi.org/10.7554/elife.50796, doi:10.7554/elife.50796. This article has 43 citations and is from a domain leading peer-reviewed journal.

25. (malumbres2011physiologicalrelevanceof pages 8-10): Marcos Malumbres. Physiological relevance of cell cycle kinases. Physiological Reviews, 91:973-1007, Jul 2011. URL: https://doi.org/10.1152/physrev.00025.2010, doi:10.1152/physrev.00025.2010. This article has 300 citations and is from a highest quality peer-reviewed journal.

26. (mishra2021cdc7mediatedphosphorylationof pages 1-2): Prashant K. Mishra, Henry Wood, John Stanton, Wei-Chun Au, Jessica R. Eisenstatt, Lars Boeckmann, Robert A. Sclafani, Michael Weinreich, Kerry S. Bloom, Peter H. Thorpe, and Munira A. Basrai. Cdc7-mediated phosphorylation of cse4 regulates high-fidelity chromosome segregation in budding yeast. Molecular Biology of the Cell, Nov 2021. URL: https://doi.org/10.1091/mbc.e21-06-0323, doi:10.1091/mbc.e21-06-0323. This article has 19 citations and is from a domain leading peer-reviewed journal.

27. (montagnoli2002drf1anovel pages 1-2): A. Montagnoli, Roberta Bosotti, Fabrizio Villa, M. Rialland, Deborah Brotherton, C. Mercurio, J. Berthelsen, and Corrado Santocanale. Drf1, a novel regulatory subunit for human cdc7 kinase. The EMBO Journal, 21:3171-3181, Jun 2002. URL: https://doi.org/10.1093/emboj/cdf290, doi:10.1093/emboj/cdf290. This article has 112 citations.

28. (montagnoli2002drf1anovel pages 10-11): A. Montagnoli, Roberta Bosotti, Fabrizio Villa, M. Rialland, Deborah Brotherton, C. Mercurio, J. Berthelsen, and Corrado Santocanale. Drf1, a novel regulatory subunit for human cdc7 kinase. The EMBO Journal, 21:3171-3181, Jun 2002. URL: https://doi.org/10.1093/emboj/cdf290, doi:10.1093/emboj/cdf290. This article has 112 citations.

29. (nakamura2002novelfissionyeast pages 11-12): Taro Nakamura, Michiko Nakamura-Kubo, Tomohiro Nakamura, and Chikashi Shimoda. Novel fission yeast cdc7-dbf4-like kinase complex required for the initiation and progression of meiotic second division. Molecular and Cellular Biology, 22:309-320, Jan 2002. URL: https://doi.org/10.1128/mcb.22.1.309-320.2002, doi:10.1128/mcb.22.1.309-320.2002. This article has 67 citations and is from a domain leading peer-reviewed journal.

30. (rainey2013cdc7dependentandindependent pages 3-4): Michael Rainey, Brendan Harhen, Guan-Nan Wang, Paul Murphy, and Corrado Santocanale. Cdc7-dependent and -independent phosphorylation of claspin in the induction of the dna replication checkpoint. Cell Cycle, 12:1560-1568, May 2013. URL: https://doi.org/10.4161/cc.24675, doi:10.4161/cc.24675. This article has 46 citations and is from a peer-reviewed journal.

31. (rainey2013cdc7dependentandindependent pages 4-6): Michael Rainey, Brendan Harhen, Guan-Nan Wang, Paul Murphy, and Corrado Santocanale. Cdc7-dependent and -independent phosphorylation of claspin in the induction of the dna replication checkpoint. Cell Cycle, 12:1560-1568, May 2013. URL: https://doi.org/10.4161/cc.24675, doi:10.4161/cc.24675. This article has 46 citations and is from a peer-reviewed journal.

32. (rainey2020cdc7kinasepromotes pages 8-11): Michael D Rainey, Aisling Quinlan, Chiara Cazzaniga, Sofija Mijic, Oliviano Martella, Jana Krietsch, Anja Göder, Massimo Lopes, and Corrado Santocanale. Cdc7 kinase promotes mre11 fork processing, modulating fork speed and chromosomal breakage. EMBO reports, Jun 2020. URL: https://doi.org/10.15252/embr.201948920, doi:10.15252/embr.201948920. This article has 37 citations and is from a highest quality peer-reviewed journal.

33. (sasi2014thepotentcdc7dbf4 pages 13-13): N. Sasi, Kanchan Tiwari, F.-F. Soon, D. Bonte, Tong Wang, K. Melcher, H. Xu, and M. Weinreich. The potent cdc7-dbf4 (ddk) kinase inhibitor xl413 has limited activity in many cancer cell lines and discovery of potential new ddk inhibitor scaffolds. PLoS ONE, Nov 2014. URL: https://doi.org/10.1371/journal.pone.0113300, doi:10.1371/journal.pone.0113300. This article has 43 citations and is from a peer-reviewed journal.

34. (yamada2014regulationandroles pages 1-2): Masayuki Yamada, Hisao Masai, and Jiri Bartek. Regulation and roles of cdc7 kinase under replication stress. Cell Cycle, 13:1859-1866, May 2014. URL: https://doi.org/10.4161/cc.29251, doi:10.4161/cc.29251. This article has 50 citations and is from a peer-reviewed journal.

35. (yang2019cdc7activatesreplication pages 1-2): Chi-Chun Yang, Hiroyuki Kato, Mayumi Shindo, and Hisao Masai. Cdc7 activates replication checkpoint by phosphorylating the chk1-binding domain of claspin in human cells. eLife, Dec 2019. URL: https://doi.org/10.7554/elife.50796, doi:10.7554/elife.50796. This article has 43 citations and is from a domain leading peer-reviewed journal.

36. (yang2019cdc7activatesreplication pages 13-14): Chi-Chun Yang, Hiroyuki Kato, Mayumi Shindo, and Hisao Masai. Cdc7 activates replication checkpoint by phosphorylating the chk1-binding domain of claspin in human cells. eLife, Dec 2019. URL: https://doi.org/10.7554/elife.50796, doi:10.7554/elife.50796. This article has 43 citations and is from a domain leading peer-reviewed journal.

37. (yang2019cdc7activatesreplication pages 2-3): Chi-Chun Yang, Hiroyuki Kato, Mayumi Shindo, and Hisao Masai. Cdc7 activates replication checkpoint by phosphorylating the chk1-binding domain of claspin in human cells. eLife, Dec 2019. URL: https://doi.org/10.7554/elife.50796, doi:10.7554/elife.50796. This article has 43 citations and is from a domain leading peer-reviewed journal.

38. (yang2019cdc7activatesreplication pages 22-23): Chi-Chun Yang, Hiroyuki Kato, Mayumi Shindo, and Hisao Masai. Cdc7 activates replication checkpoint by phosphorylating the chk1-binding domain of claspin in human cells. eLife, Dec 2019. URL: https://doi.org/10.7554/elife.50796, doi:10.7554/elife.50796. This article has 43 citations and is from a domain leading peer-reviewed journal.

39. (cheng2022structuralinsightinto pages 11-12): Jiaxuan Cheng, Ningning Li, Yunjing Huo, S. Dang, B. Tye, N. Gao, and Y. Zhai. Structural insight into the mcm double hexamer activation by dbf4-cdc7 kinase. Nature Communications, Mar 2022. URL: https://doi.org/10.1038/s41467-022-29070-5, doi:10.1038/s41467-022-29070-5. This article has 31 citations and is from a highest quality peer-reviewed journal.